8-K: Rafael Holdings Reports Increased Losses in First Quarter of Fiscal Year 2025 Amidst Cyclo Therapeutics Merger Plans

Rafael Holdings reported a net loss of $9.0 million for the first quarter of fiscal year 2025, driven by unrealized losses on its investment in Cyclo Therapeutics, as it prepares for a merger with the company.

Summary

• Rafael Holdings reported its financial results for the first quarter of fiscal year 2025, which ended on October 31, 2024.
• The company recorded a net loss attributable to Rafael Holdings of $9.0 million, or $0.37 per share, compared to a net loss of $3.6 million, or $0.15 per share, in the same period last year.
• The increased losses are primarily due to $6.0 million in unrealized losses on the company's investment in Cyclo Therapeutics and convertible notes receivable from Cyclo, compared to $2.1 million in unrealized losses in the prior year.
• Research and development expenses increased to $1.3 million from $0.5 million year-over-year, due to the consolidation of Cornerstone and Day Three.
• General and administrative expenses rose to $2.5 million from $2.0 million, primarily due to additional expenses from Cornerstone and Day Three, as well as increased professional fees related to the proposed Cyclo merger.
• As of October 31, 2024, Rafael Holdings had $54.3 million in cash, cash equivalents, and marketable securities.
• The company anticipates a shareholder vote on the pending merger agreement with Cyclo Therapeutics in the first calendar quarter of 2025, with closing expected shortly after approvals.
• Upon closing the merger, Rafael Holdings intends to focus its strategic efforts on Trappsol Cyclo, Cyclo's lead clinical program.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the increased losses and reliance on a single clinical program. However, the company has a clear strategic direction and a significant cash position.

Positives

• Rafael Holdings has $54.3 million in cash, cash equivalents, and marketable securities.
• The company is moving forward with the merger with Cyclo Therapeutics, which will allow them to focus on Trappsol Cyclo.
• Cyclo Therapeutics has fully enrolled its pivotal Phase 3 study for Trappsol Cyclo, with interim results expected in mid-2025.
• Management believes Trappsol Cyclo has the potential to be a market leader despite recent FDA approvals of other treatments for NPC Type C1.

Negatives

• The company reported a net loss of $9.0 million for the quarter, a significant increase from the $3.6 million loss in the same period last year.
• The increased losses are primarily due to unrealized losses on investments in Cyclo Therapeutics.
• Research and development expenses and general and administrative expenses have increased year-over-year.

Risks

• The company's financial results are heavily influenced by the performance of its investment in Cyclo Therapeutics.
• The merger with Cyclo Therapeutics is subject to shareholder approval and may not be completed.
• The success of Trappsol Cyclo is not guaranteed, and there are other treatments for NPC Type C1 on the market.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company intends to focus its strategic efforts and resources on Trappsol Cyclo after the merger with Cyclo Therapeutics is completed. The company is also evaluating its other operating entities and portfolio of assets.

Management Comments

• Bill Conkling, CEO of Rafael Holdings, stated that the company is evaluating its other operating entities and portfolio of assets.
• Bill Conkling also mentioned that they are encouraged by Cyclo Therapeutics fully enrolling its pivotal Phase 3 study for Trappsol Cyclo and that they believe Trappsol Cyclo has the potential to be a market leader.

Industry Context

This announcement comes as Rafael Holdings is preparing for a merger with Cyclo Therapeutics, indicating a strategic shift towards focusing on a specific clinical program. The mention of other treatments for NPC Type C1 highlights the competitive landscape in the rare disease therapeutics market.

Comparison to Industry Standards

• The increased losses at Rafael Holdings are concerning, especially when compared to other pharmaceutical companies that are successfully commercializing products or have strong pipelines.
• The company's reliance on the success of Trappsol Cyclo is a risk, as many biotech companies diversify their portfolios to mitigate the risk of clinical trial failures.
• The increase in R&D and G&A expenses is not unusual for a company in the clinical stage, but the magnitude of the increase should be monitored closely.
• Companies like BioMarin Pharmaceutical and Alexion Pharmaceuticals, which have successfully developed and commercialized treatments for rare diseases, serve as benchmarks for Rafael Holdings' future performance.

Stakeholder Impact

• Shareholders will be impacted by the increased losses and the potential risks associated with the merger and the success of Trappsol Cyclo.
• Employees may experience changes as the company focuses on the merged entity and evaluates its other operating entities.
• Customers of the company's various subsidiaries may see changes in product offerings or services as the company shifts its focus.
• Suppliers and creditors may be impacted by the company's financial performance and strategic direction.

Next Steps

• The company will proceed to a shareholder vote on the merger agreement with Cyclo Therapeutics in the first calendar quarter of 2025.
• The company will close the merger promptly after shareholder approvals.
• The company will focus its strategic efforts and resources on Trappsol Cyclo after the merger.
• The company will continue to evaluate its other operating entities and portfolio of assets.
• Cyclo Therapeutics will release the 48-week interim analysis results from its Phase 3 study of Trappsol Cyclo in the middle of 2025.

Key Dates

Keywords

Rafael Holdings, Cyclo Therapeutics, Merger, Trappsol Cyclo, Niemann-Pick Disease Type C1, Financial Results, Net Loss, Research and Development, Investment, Pharmaceuticals